TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02063061

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Patients will receive simulated treatment, with the same ESWT unit as in other arm. Placebo gel-pad is design to prevent shockwaves emission. Looks identical as active gel-pad.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT treatment
Description: ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ESWT treatment
Description: ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
Study: NCT00383760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study: NCT00602459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV or PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04073927

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium butyrate
Description: Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium butyrate
Description: Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane.
Study: NCT03057795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00777296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARIKACE™
Description: Study start date is before Jan 18, 2017.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARIKACE™
Description: Study start date is before Jan 18, 2017.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study start date is before Jan 18, 2017.
Study: NCT03057795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00777296

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study start date is before Jan 18, 2017.
Study: NCT04075214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular neurostimulation (tAN)
Description: Phoenix tAN system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous auricular neurostimulation (tAN)
Description: Phoenix tAN system
Study: NCT01610882

Intervention type: DEVICE
Group type: OTHER
Intervention: Panda first followed by manual pain assessment
Description: Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Panda will be used first, manual method 5 mins later.
Study: NCT01022437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geranium Oil with component PN-34
Description: Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
Study: NCT01808157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01561248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol solution for daily bowel lavage.
Description: At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
Study: NCT02599194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FSPG
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Administered intravenously (IV)
Study: NCT01752504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization
Description: The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
Study: NCT01610882

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual first followed by Panda pain assessment
Description: Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Manual method will be used first, Panda 5 mins later.
Study: NCT03574285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anpl-one SR Tab. 300mg
Description: Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anpl-one SR Tab. 300mg
Description: Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpodipil SR Tab. 300mg
Description: Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpodipil SR Tab. 300mg
Description: Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
Study: NCT01592786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride (HCl)
Description: Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
Study: NCT03742362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scans of distal radius
Description: MRI scans to monitor the fat fraction in the bone marrow of the distal radius
Study: NCT03596801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV 6120/∆NS1
Description: Delivered as nose drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV 6120/∆NS1
Description: Delivered as nose drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV 6120/F1/G2/∆NS1
Description: Delivered as nose drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV 6120/F1/G2/∆NS1
Description: Delivered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered as nose drops
Study: NCT03682848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG + 3TC FDC
Description: DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.
Study: NCT03538288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS will be applied at 10 Hz to the DLPFC
Study: NCT01018927

Intervention type: DEVICE
Intervention: Administering three additional MRI images
Description: Three additional MRI images to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
Study: NCT03367182

Intervention type: DRUG
Intervention: Weekly paclitaxel
Description: Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle

Intervention type: DRUG
Intervention: Topotecan
Description: Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle

Intervention type: DRUG
Intervention: Pegylated liposomal doxorubicin
Description: Drug: liposomal doxorubicin 40mg/m2 iv every 4 weeks

Intervention type: DRUG
Intervention: Bevacizumab
Description: Drug: bevacizumab \[Avastin\] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks

Intervention type: DRUG
Intervention: Bevacizumab
Description: Drug: bevacizumab \[Avastin\] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks

Intervention type: DRUG
Intervention: Bevacizumab
Description: Drug: bevacizumab \[Avastin\] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
Study: NCT03603912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin ER 500 mg daily, titrated at 1 month intervals to 500 mg twice daily, then 750 mg twice daily, as tolerated, for 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin ER 500 mg daily, titrated at 1 month intervals to 500 mg twice daily, then 750 mg twice daily, as tolerated, for 2 years.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle/Risk Factor Modification
Description: Diet/nutrition counseling and exercise prescription with follow-up visits, sleep apnea screening and treatment if detected, optimization of guideline-directed medical therapies for hypertension, coronary artery disease (CAD), hyperlipidemia and heart failure (HF).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle/Risk Factor Modification
Description: Diet/nutrition counseling and exercise prescription with follow-up visits, sleep apnea screening and treatment if detected, optimization of guideline-directed medical therapies for hypertension, coronary artery disease (CAD), hyperlipidemia and heart failure (HF).
Study: NCT05220449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-frequency dual-site tACS
Description: Dual site transcranial alternating current stimulation over the primary visual cortex (V1) and the mediotemporal cortex (MT/V5) using two different stimulation frequencies (Alpha and Gamma)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-frequency dual-site tACS
Description: Dual site transcranial alternating current stimulation over the primary visual cortex (V1) and the mediotemporal cortex (MT/V5) using two different stimulation frequencies (Alpha and Gamma)
Study: NCT01983540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine
Description: DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine
Description: DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age) and a booster dose of Infanrix hexa vaccine with Prevnar at 12 to 24 months of age in a previous study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa + Prevenar + Rotarix vaccine
Description: Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster dose of DTaP-IPV-Hep B-PRP\~T vaccine concomitantly with Prevenar vaccine concomitantly with Prevenar at 12 to 24 months of age in a previous study.
Study: NCT02965001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-AE105
Description: The patients are refered to an uPAR-PET/CT scan before initiation of the routine radiotherapy and the prognostic efficacy is assessed by registration of recurrence rate and death at routine clinical follow-up.
Study: NCT01354652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir, lamivudine
Description: entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.~lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir, lamivudine
Description: entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.~lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.
Study: NCT00950014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Presentation of drug efficacy and side effect data
Description: Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of drug efficacy and side effect data
Description: Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of drug efficacy and side effect data
Description: Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of drug efficacy and side effect data
Description: Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presentation of drug efficacy and side effect data
Description: Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
Study: NCT03168711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine
Description: Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
Study: NCT00351468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag olamine (SB-497115-GR)
Description: Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
Study: NCT04670549

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of treatment guidelines
Description: To improve knowledge of OA treatment recommendations among people with hip and knee OA, a lay language summary will be emailed all OA patient participants. A second summary of the treatment recommendations, targeting general practitioners (GPs) will also be emailed the OA patient participants. The patients will be encouraged to print and bring this summary to their GP at the next visit (user-initiated implementation). Barriers and facilitators for providing evidence-based OA care among primary care physiotherapists will be mapped through interviews. Thereafter, a tool-kit of strategies and practical aids intended to help overcome these barriers will be developed and made available for the physiotherapists.
Study: NCT01466686

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Fractionated Radiation Therapy (LDFRT)
Description: All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If \> 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
Study: NCT03955692

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
Study: NCT00891774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVOLENCE®
Description: Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
Study: NCT03129737

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve surgery
Description: Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.
Study: NCT02158585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
Study: NCT03129737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery
Description: Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.
Study: NCT02158585

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will match the lamotrigine dosage, frequency and duration.
Study: NCT03129737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid valve annuloplasty
Description: Depending on the extent of the valve disease, there is the possibility to perform valve repair. In mitral valve reference center the rate of repair will reach 100%. In many patients with mitral valve regurgitation, tricuspid valve will be insufficient or the annulus dilated. Tricuspid annuloplasty ring will be helpful to treat dilation by reshaping, or to treat the regurgitant diseases. The ring will be secured and sutured to the native annulus by U-stitches.
Study: NCT03526367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydration plus rosuvastatin therapy
Description: In experimental group,a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days and hydration（3ml/kg/h）last 12 hours after randomized

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Prohibition of use any statins from randomized to 12 hours after procedure; The hydration or not is determined by physicians but 1 ml/kg/h at most.